Bristol-Myers Squibb Earnings: What Investors Should Watch
Bristol-Myers Squibb (NYSE:BMY) will report earnings before markets open on Thursday, July 25th. Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
Here is your Cheat Sheet to Bristol-myers Squibb Earnings:
Earnings Expectations: Analysts expect earnings of $0.44 per share on revenues of $4.05 billion. Currently, the company’s P/E ratio stands at 49.77.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.48 to a profit $0.47. For the current year, the average estimate is a profit of $1.8, which is worse than the estimate ninety days ago.
Here’s how Bristol-myers Squibb has been performing on an annual basis:
|Revenue ($) in millions||20,597||18,808||19,484||21,244||17,621|
|Diluted EPS ($)||2.63||5.34||1.79||2.16||1.16|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||4,443.00||3,736.00||4,191.00||3,831.00|
|Diluted EPS ($)||0.38||-0.43||0.56||0.37|
Bristol-myers Squibb has beat analyst estimates 1 time in the past four quarters. This is not consistent enough to get bullish yet.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)